Effect of vaccination patterns and vaccination rates on the spread and mortality of the COVID-19 pandemic

Chen, Yi-Tui

doi:10.1016/j.hlpt.2022.100699

Cited by 11 publications

(9 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in a recent study, COVID-19 was effectively combated with a Geographic Information System-based face mask distribution system and QR code registration system in Taiwan. 14 We think that with the integration of AI technologies such as ChatGPT into digital health systems, digitalized health can take a step forward, especially facilitating the management of patients with rheumatic diseases.…”

Section: Discussionmentioning

confidence: 99%

“Dr ChatGPT”: Is it a reliable and useful source for common rheumatic diseases?

Uz¹,

Umay²

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

The use of digital technologies such as telemedicine, patient tracking systems, and patient registration systems in health care has been a topic of focus in recent years. Artificial intelligence (AI) technology will facilitate the work of patients and healthcare professionals in this field. Artificial intelligence is defined as a technology that emerged with the question of whether machines can think and now enables machines to produce solutions to complex problems as humans do, and to imitate the way humans think. 1 Artificial intelligence consists of components such as machine learning, deep learning, natural language processing, and expert systems, and AI-based chatbots are used in the field of health for diagnosis, screening, and treatment. In the field of health, many chatbots such as Woebot, Your.MD, HealthTap, Cancer Chatbot, VitaminBot, Babylon Health, Safedrugbot, and Ada Health are used for various purposes.

show abstract

Section: Discussionmentioning

confidence: 99%

“Dr ChatGPT”: Is it a reliable and useful source for common rheumatic diseases?

Uz¹,

Umay²

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

“…Age, sex, COVID-19 vaccination status, severity on admission, and treatment all influence the prognosis of COVID-19. [15][16][17] Therefore, these factors were considered potential confounding factors in our study. Furthermore, comorbidities, such as hypertension, diabetes, coronary heart disease, hepatitis, chronic obstructive pulmonary disease (COPD), and chronic kidney disease (CKD) are all factors associated with poor prognosis in COVID-19.…”

Section: Discussionmentioning

confidence: 99%

“…The median (IQR) overall length of hospital stay was 9 (6)(7)(8)(9)(10)(11)(12)(13)(14) days. The overall median (IQR) follow-up period was 12 (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18) days.…”

Section: Patient Cohort and Study Designmentioning

confidence: 99%

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19

Hu,

Cui,

Lei

et al. 2023

IDR

View full text Add to dashboard Cite

To compare the effectiveness of azvudine and nirmatrelvir/ritonavir for the treatment of coronavirus disease . Patients and Methods: We conducted a retrospective analysis of data from 576 patients with COVID-19, comprising 195 patients without antiviral therapy, 226 patients treated with azvudine, 114 patients treated with nirmatrelvir/ritonavir, and 41 patients were treated with azvudine and nirmatrelvir/ritonavir concurrently. We compared their symptoms, mortality rates, and the length and cost of hospitalization.Results: The incidence of symptoms was similar in patients treated with azvudine and in those treated with nirmatrelvir/ritonavir. However, among patients experiencing weakness, the duration of weakness was significantly shorter in the azvudine group than in the nirmatrelvir/ ritonavir group (P=0.029). Mortality did not differ significantly between the azvudine group and the nirmatrelvir/ritonavir group (18.14% vs.10.53%, P=0.068). Among "severe patients", the mortality rate was markedly lower in patients treated with nirmatrelvir/ritonavir than in patients treated with azvudine (16.92% vs.32.17%, P=0.026). In patients with hepatic insufficiency, those treated with nirmatrelvir/ritonavir had substantially lower mortality than those treated with azvudine (15.09% vs.34.25%, P=0.016). In addition, patients treated with nirmatrelvir/ ritonavir had longer hospital stays (P=0.002) and higher hospital costs (P<0.001) than those receiving azvudine. Compared with patients treated with nirmatrelvir/ritonavir or azvudine alone, patients taking nirmatrelvir/ritonavir and azvudine concurrently had no significant improvement in survival (P>0.05), length of stay (P>0.05), or hospital costs (P>0.05). Conclusion: Azvudine is recommended for patients with non-severe COVID-19 with weakness. Nirmatrelvir/ritonavir is recommended for patients with severe COVID-19, to reduce mortality, and it could be the best choice for patients with hepatic insufficiency. The concurrent use of nirmatrelvir/ritonavir and azvudine in patients with COVID-19 could be not recommended.

show abstract

“…Along with these considerations, it was plainly pointed out, on a fairly comprehensive scale (150 countries), that the greater the welfare, the larger the leaning towards vaccination [ 45 ]. So, the patterns of COVID-19 vaccination can appear as a result of a number of elements, and Chen [ 46 ] illustrates that the full speed vaccination prototype influences the most the COVID-19 spread and deaths. The decrease in the number of COVID-19 cases and deaths can be attributed to vaccination, income and education, as Cengiz et al [ 47 ] revealed; specifically, they inventoried the situation of COVID-19 vaccination in the cities of Turkey and established that, both in the case of women and men who have a secondary education or who have interrupted their studies at a certain moment, there is a reluctance to vaccinate, while among those who followed university studies, there is a positive correlation with this, the per capita income leading to the registration of the same trend [ 47 ].…”

Section: Literature Reviewmentioning

confidence: 99%